Home โบ Leukemia
Leukemia clinical trials recruiting in the U.S.
102 studies for Leukemia are recruiting participants at sites across the United States.
Leukemia is cancer of the white blood cells. There are two types of Leukemias, acute and chronic. Learn about the differences and treatments available.
Cities with the most studies
- Houston, TX28 studies
- Boston, MA25 studies
- New York City, NY19 studies
- Los Angeles, CA16 studies
- Chicago, IL16 studies
- Durham, NC13 studies
- Philadelphia, PA12 studies
- Nashville, TN12 studies
- Columbus, OH12 studies
- Baldwin Park, CA12 studies
- Milwaukee, WI11 studies
- Seattle, WA11 studies
- Aurora, CO10 studies
- Atlanta, GA10 studies
- Birmingham, AL10 studies
- Cincinnati, OH9 studies
- Edison, NJ9 studies
- Mountain View, CA9 studies
- Miami, FL9 studies
- New Haven, CT8 studies
- Dallas, TX8 studies
- Queens, NY8 studies
- Portland, OR8 studies
- Denver, CO7 studies
- Buffalo, NY7 studies
- Clifton, NJ7 studies
- Orange, CA7 studies
- Washington, DC7 studies
- Tampa, FL7 studies
- Omaha, NE6 studies
- Cedar Rapids, IA6 studies
- Cleveland, OH5 studies
- Rochester, MN5 studies
- Baltimore, MD5 studies
- Ann Arbor, MI5 studies
- San Diego, CA5 studies
- Charlottesville, VA5 studies
- Charlotte, NC5 studies
- Memphis, TN5 studies
- Hartford, CT4 studies
By state
- Alabama10 studies
- Arizona7 studies
- California28 studies
- Colorado15 studies
- Connecticut11 studies
- Florida17 studies
- Georgia12 studies
- Illinois17 studies
- Indiana4 studies
- Iowa7 studies
- Kansas5 studies
- Kentucky6 studies
- Louisiana3 studies
- Maine3 studies
- Maryland11 studies
- Massachusetts28 studies
- Michigan8 studies
- Minnesota9 studies
- Missouri6 studies
- Nebraska6 studies
- New Jersey15 studies
- New Mexico3 studies
- New York26 studies
- North Carolina20 studies
- Ohio26 studies
- Oklahoma4 studies
- Oregon9 studies
- Pennsylvania15 studies
- Rhode Island4 studies
- South Carolina6 studies
- Tennessee14 studies
- Texas31 studies
- Utah4 studies
- Vermont4 studies
- Virginia7 studies
- Washington11 studies
- Wisconsin13 studies
Recently updated studies
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
RecruitingObservational study
Ages 18 to 110 ยท All sexes ยท Updated Sep 28, 2026 ยท NCT00923507Rutgers University Study of the Genetics of Blood Cancers
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 110 ยท All sexes ยท Updated Sep 25, 2026 ยท NCT07714044Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
RecruitingPhase 3
Ages 18 to 71 ยท All sexes ยท Updated Sep 23, 2026 ยท NCT07504458Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
RecruitingPhase 2
Ages 1 to 25 ยท All sexes ยท Updated Sep 23, 2026 ยท NCT05645718Natural History Study of GATA2 Deficiency and Related Disorders
RecruitingObservational studyHealthy volunteers welcome
Ages 2 to 100 ยท All sexes ยท Updated Sep 22, 2026 ยท NCT01905826Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
RecruitingPhase 1
Up to age 75 ยท All sexes ยท Updated Sep 16, 2026 ยท NCT06345027Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 16, 2026 ยท NCT06824168A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
RecruitingPhase 1/2
30 Days ยท All sexes ยท Updated Sep 16, 2026 ยท NCT04065399A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
RecruitingPhase 1
Up to age 25 ยท All sexes ยท Updated Sep 15, 2026 ยท NCT06810583(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 15, 2026 ยท NCT04996875A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
RecruitingPhase 2
Ages 12 and older ยท All sexes ยท Updated Sep 11, 2026 ยท NCT06229912Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
Recruiting
Ages 18 and older ยท All sexes ยท Updated Sep 9, 2026 ยท NCT06907797Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
RecruitingPhase 3
Ages 18 to 18 ยท All sexes ยท Updated Sep 8, 2026 ยท NCT07509151Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 2, 2026 ยท NCT07249346Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
RecruitingPhase 2
Ages 1 to 18 ยท All sexes ยท Updated Sep 2, 2026 ยท NCT07354074First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Sep 1, 2026 ยท NCT07586618Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
RecruitingPhase 1
Ages 1 to 25 ยท All sexes ยท Updated Sep 1, 2026 ยท NCT06408194Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
RecruitingObservational studyHealthy volunteers welcome
Ages 5 and older ยท All sexes ยท Updated Aug 31, 2026 ยท NCT05237986Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Aug 28, 2026 ยท NCT07284433CIML NK Cells With Venetoclax for AML
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Aug 28, 2026 ยท NCT06152809Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
RecruitingPhase 1
Ages 18 to 90 ยท All sexes ยท Updated Aug 26, 2026 ยท NCT07439211Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
RecruitingPhase 1
18 Months โ 39 Years ยท All sexes ยท Updated Aug 21, 2026 ยท NCT07573111Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Aug 20, 2026 ยท NCT06001788Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Aug 20, 2026 ยท NCT07007312Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
Recruiting
Ages 19 and older ยท All sexes ยท Updated Aug 19, 2026 ยท NCT04898790From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.